Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
Identifieur interne : 002630 ( Main/Corpus ); précédent : 002629; suivant : 002631Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
Auteurs : Russell C. Callaghan ; James K. Cunningham ; Gautam Sajeev ; Stephen J. KishSource :
- Movement Disorders [ 0885-3185 ] ; 2010-10-30.
English descriptors
Abstract
Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23263
Links to Exploration step
ISTEX:2953724CA123F4AB4F11A4E7F19C3173786C0FCFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title><author><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name><affiliation><mods:affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name><affiliation><mods:affiliation>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona, USA</mods:affiliation></affiliation></author><author><name sortKey="Sajeev, Gautam" sort="Sajeev, Gautam" uniqKey="Sajeev G" first="Gautam" last="Sajeev">Gautam Sajeev</name><affiliation><mods:affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation><mods:affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2953724CA123F4AB4F11A4E7F19C3173786C0FCF</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23263</idno><idno type="url">https://api.istex.fr/document/2953724CA123F4AB4F11A4E7F19C3173786C0FCF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002630</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title><author><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name><affiliation><mods:affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name><affiliation><mods:affiliation>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona, USA</mods:affiliation></affiliation></author><author><name sortKey="Sajeev, Gautam" sort="Sajeev, Gautam" uniqKey="Sajeev G" first="Gautam" last="Sajeev">Gautam Sajeev</name><affiliation><mods:affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation><mods:affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-10-30">2010-10-30</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2333">2333</biblScope><biblScope unit="page" to="2339">2339</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2953724CA123F4AB4F11A4E7F19C3173786C0FCF</idno><idno type="DOI">10.1002/mds.23263</idno><idno type="ArticleID">MDS23263</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>incidence</term><term>longitudinal</term><term>methamphetamine</term><term>parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Russell C. Callaghan PhD</name><affiliations><json:string>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</json:string><json:string>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>James K. Cunningham PhD</name><affiliations><json:string>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona, USA</json:string></affiliations></json:item><json:item><name>Gautam Sajeev MSc</name><affiliations><json:string>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Stephen J. Kish PhD</name><affiliations><json:string>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</json:string><json:string>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>methamphetamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>incidence</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>longitudinal</value></json:item></subject><articleId><json:string>MDS23263</json:string></articleId><language><json:string>eng</json:string></language><abstract>Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>7.405</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1783</abstractCharCount><pdfWordCount>4405</pdfWordCount><pdfCharCount>30678</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>250</abstractWordCount></qualityIndicators><title>Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>2339</last><first>2333</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23263</json:string></doi><id>2953724CA123F4AB4F11A4E7F19C3173786C0FCF</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2953724CA123F4AB4F11A4E7F19C3173786C0FCF/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2953724CA123F4AB4F11A4E7F19C3173786C0FCF/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2953724CA123F4AB4F11A4E7F19C3173786C0FCF/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Dr. Callaghan: This research was supported by an indirect institutional grant from the Ontario Ministry of Health and Long‐Term Care to the Centre for Addiction and Mental Health (CAMH; this grant provides salary support to research scientists at CAMH). Dr. Cunningham received support from the Canada‐US Fulbright Program and the Mexico‐US Fulbright‐García Robles Program, as part of the Fulbright Canada‐Mexico Joint Award in North American Studies. Dr. S. Kish receives related research funding from: US NIH NIDA R01 DA017301 and DA025096; an Honorarium for a seminar on methamphetamine toxicity, Centre for Addiction and Mental Health, Toronto, Canada; and an expert witness fee to provide an opinion on amphetamine toxicity. Mr. G. Sajeev reports receiving no research funding in the last 12 months or at any time in his professional career.</note><note>Ontario Ministry of Health and Long‐Term Care to the Centre for Addiction and Mental Health</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title><author><persName><forename type="first">Russell C.</forename><surname>Callaghan</surname></persName><roleName type="degree">PhD</roleName><note type="correspondence"><p>Correspondence: Centre for Addiction and Mental Health, 33 Russell St., Toronto, Ontario, Canada M5S 2S1</p></note><affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</affiliation><affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">James K.</forename><surname>Cunningham</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona, USA</affiliation></author><author><persName><forename type="first">Gautam</forename><surname>Sajeev</surname></persName><roleName type="degree">MSc</roleName><affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">Stephen J.</forename><surname>Kish</surname></persName><roleName type="degree">PhD</roleName><affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</affiliation><affiliation>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-10-30"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2333">2333</biblScope><biblScope unit="page" to="2339">2339</biblScope></imprint></monogr><idno type="istex">2953724CA123F4AB4F11A4E7F19C3173786C0FCF</idno><idno type="DOI">10.1002/mds.23263</idno><idno type="ArticleID">MDS23263</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>methamphetamine</term></item><item><term>Parkinson's disease</term></item><item><term>parkinsonism</term></item><item><term>incidence</term></item><item><term>longitudinal</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-07-24">Received</change><change when="2010-04-26">Registration</change><change when="2010-10-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2953724CA123F4AB4F11A4E7F19C3173786C0FCF/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v25:14</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2010-10-30">30 October 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="110" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23263</doi><idGroup><id type="unit" value="MDS23263"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-07-24"></event><event type="manuscriptRevised" date="2010-03-10"></event><event type="manuscriptAccepted" date="2010-04-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText source:FullText result:FullText" date="2011-07-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-08-24"></event><event type="publishedOnlineFinalForm" date="2010-10-25"></event><event type="firstOnline" date="2010-08-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2333</numbering><numbering type="pageLast">2339</numbering></numberingGroup><correspondenceTo>Centre for Addiction and Mental Health, 33 Russell St., Toronto, Ontario, Canada M5S 2S1</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23263.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="55"></count><count type="wordTotal" number="5298"></count></countGroup><titleGroup><title type="main" xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders<link href="#fn1"></link></title><title type="short" xml:lang="en">Methamphetamine Use and Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Russell C.</givenNames><familyName>Callaghan</familyName><degrees>PhD</degrees></personName><contactDetails><email>Russell_Callaghan@camh.net</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>James K.</givenNames><familyName>Cunningham</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Gautam</givenNames><familyName>Sajeev</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af4"><personName><givenNames>Stephen J.</givenNames><familyName>Kish</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="CA" type="organization"><unparsedAffiliation>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">methamphetamine</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">parkinsonism</keyword><keyword xml:id="kwd4">incidence</keyword><keyword xml:id="kwd5">longitudinal</keyword></keywordGroup><fundingInfo><fundingAgency>Ontario Ministry of Health and Long‐Term Care to the Centre for Addiction and Mental Health</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, <i>P</i>= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Dr. Callaghan: This research was supported by an indirect institutional grant from the Ontario Ministry of Health and Long‐Term Care to the Centre for Addiction and Mental Health (CAMH; this grant provides salary support to research scientists at CAMH). Dr. Cunningham received support from the Canada‐US Fulbright Program and the Mexico‐US Fulbright‐García Robles Program, as part of the Fulbright Canada‐Mexico Joint Award in North American Studies. Dr. S. Kish receives related research funding from: US NIH NIDA R01 DA017301 and DA025096; an Honorarium for a seminar on methamphetamine toxicity, Centre for Addiction and Mental Health, Toronto, Canada; and an expert witness fee to provide an opinion on amphetamine toxicity. Mr. G. Sajeev reports receiving no research funding in the last 12 months or at any time in his professional career.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Methamphetamine Use and Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title></titleInfo><name type="personal"><namePart type="given">Russell C.</namePart><namePart type="family">Callaghan</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</affiliation><affiliation>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</affiliation><description>Correspondence: Centre for Addiction and Mental Health, 33 Russell St., Toronto, Ontario, Canada M5S 2S1</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James K.</namePart><namePart type="family">Cunningham</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gautam</namePart><namePart type="family">Sajeev</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen J.</namePart><namePart type="family">Kish</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</affiliation><affiliation>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-10-30</dateIssued><dateCaptured encoding="w3cdtf">2009-07-24</dateCaptured><dateValid encoding="w3cdtf">2010-04-26</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">55</extent><extent unit="words">5298</extent></physicalDescription><abstract lang="en">Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Dr. Callaghan: This research was supported by an indirect institutional grant from the Ontario Ministry of Health and Long‐Term Care to the Centre for Addiction and Mental Health (CAMH; this grant provides salary support to research scientists at CAMH). Dr. Cunningham received support from the Canada‐US Fulbright Program and the Mexico‐US Fulbright‐García Robles Program, as part of the Fulbright Canada‐Mexico Joint Award in North American Studies. Dr. S. Kish receives related research funding from: US NIH NIDA R01 DA017301 and DA025096; an Honorarium for a seminar on methamphetamine toxicity, Centre for Addiction and Mental Health, Toronto, Canada; and an expert witness fee to provide an opinion on amphetamine toxicity. Mr. G. Sajeev reports receiving no research funding in the last 12 months or at any time in his professional career.</note><note type="funding">Ontario Ministry of Health and Long‐Term Care to the Centre for Addiction and Mental Health</note><subject lang="en"><genre>Keywords</genre><topic>methamphetamine</topic><topic>Parkinson's disease</topic><topic>parkinsonism</topic><topic>incidence</topic><topic>longitudinal</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2333</start><end>2339</end><total>7</total></extent></part></relatedItem><identifier type="istex">2953724CA123F4AB4F11A4E7F19C3173786C0FCF</identifier><identifier type="DOI">10.1002/mds.23263</identifier><identifier type="ArticleID">MDS23263</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002630 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002630 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:2953724CA123F4AB4F11A4E7F19C3173786C0FCF
|texte= Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
}}
| This area was generated with Dilib version V0.6.23. |  |